# Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss

> **NCT03603314** · PHASE2,PHASE3 · COMPLETED · sponsor: **Sensorion** · enrollment: 115 (actual)

## Conditions studied

- Severe Sudden Sensorineural Hearing Loss

## Interventions

- **DRUG:** SENS-401
- **OTHER:** Placebo Oral Tablet
- **DRUG:** SENS-401

## Key facts

- **NCT ID:** NCT03603314
- **Lead sponsor:** Sensorion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-15
- **Primary completion:** 2021-11-04
- **Final completion:** 2022-01-12
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03603314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03603314, "Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03603314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*